Neurocrine Biosciences (NBIX) Change in Receivables (2010 - 2026)

Neurocrine Biosciences has reported Change in Receivables for 17 years, with the latest figure at $81.4 million in Q1 2026.

• For the quarter ending Q1 2026, Change in Receivables rose 120.6% year-over-year to $81.4 million; the trailing twelve-month figure through Mar 2026 stood at $255.0 million (up 289.91% YoY), and the FY2025 full-year result was $210.5 million, up 428.89% from the prior year.
• Change in Receivables for Q1 2026 stood at $81.4 million, up from -$38.4 million in the prior quarter.
• The five-year high for Change in Receivables was $132.3 million in Q3 2025, with the low at -$38.4 million in Q4 2025.
• Historically, Change in Receivables has averaged $34.3 million across 5 years, with a median of $22.2 million in 2022.
• Annual changes were most pronounced in 2022 — Change in Receivables surged 938.71% — and 2025, when it plunged 1820.0%.
• Neurocrine Biosciences' Change in Receivables stood at $46.5 million in 2022, then tumbled by 53.98% to $21.4 million in 2023, then tumbled by 109.35% to -$2.0 million in 2024, then sank by 1820.0% to -$38.4 million in 2025, then surged by 311.98% to $81.4 million in 2026.
• The last three Change in Receivables figures came in at $81.4 million (Q1 2026), -$38.4 million (Q4 2025), and $132.3 million (Q3 2025), per Business Quant data.